Your browser is no longer supported. Please, upgrade your browser.
ASNS Arsanis, Inc. daily Stock Chart
Arsanis, Inc.
Index- P/E- EPS (ttm)-3.14 Insider Own1.80% Shs Outstand15.05M Perf Week-2.50%
Market Cap52.83M Forward P/E- EPS next Y-1.92 Insider Trans- Shs Float6.46M Perf Month187.70%
Income-44.90M PEG- EPS next Q-0.68 Inst Own75.50% Short Float18.18% Perf Quarter104.07%
Sales- P/S- EPS this Y-11.60% Inst Trans-5.25% Short Ratio0.63 Perf Half Y-78.86%
Book/sh1.95 P/B1.80 EPS next Y36.60% ROA-70.80% Target Price13.13 Perf Year-69.82%
Cash/sh2.71 P/C1.29 EPS next 5Y- ROE-103.80% 52W Range1.15 - 28.69 Perf YTD-72.49%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-88.26% Beta-
Dividend %- Quick Ratio5.10 Sales past 5Y- Gross Margin- 52W Low193.04% ATR0.64
Employees40 Current Ratio5.10 Sales Q/Q- Oper. Margin- RSI (14)57.50 Volatility17.38% 31.23%
OptionableNo Debt/Eq0.38 EPS Q/Q29.10% Profit Margin- Rel Volume0.29 Prev Close3.51
ShortableYes LT Debt/Eq0.28 Earnings- Payout- Avg Volume1.88M Price3.37
Recom2.80 SMA2015.41% SMA5064.13% SMA200-63.33% Volume538,889 Change-3.99%
Dec-11-18 07:40AM  Report: Exploring Fundamental Drivers Behind GTT Communications, Midstates Petroleum, Arsanis, BioTelemetry, Dolby Laboratories, and Northern Dynasty Minerals New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
07:38AM  New Strong Sell Stocks for December 11th Zacks
Dec-03-18 07:30AM  Arsanis Shares Soar on Recent Merger Agreement, Analysts Review and Target Price ACCESSWIRE -13.11%
Nov-29-18 11:00AM  Biotech's Tackling Major Issues You Should Know ACCESSWIRE +21.24%
Nov-28-18 03:43PM  Arsanis, X4 Pharmaceuticals Announce Merger Deal With Rare Disease Focus Benzinga -25.73%
06:50AM  Todays Research Reports on Stocks to Watch: Arsanis and Aethlon Medical ACCESSWIRE
05:50AM  Arsanis may face more layoffs after merger with X4 Pharma American City Business Journals
Nov-27-18 01:30PM  SHAREHOLDER ALERT: WeissLaw LLP Investigates Arsanis, Inc. ACCESSWIRE +255.17%
10:10AM  The Reason Healthcare Stocks Are Being Called Home By Investors ACCESSWIRE
07:00AM  Arsanis and X4 Pharmaceuticals Agree to Merger GlobeNewswire
Nov-09-18 08:00AM  Arsanis Reports Financial Results for Third Quarter 2018 GlobeNewswire
Oct-17-18 07:20AM  Investor Expectations to Drive Momentum within Arsanis, Dynavax Technologies, Puma Biotechnology, Opko Health, Adaptimmune Therapeutics, and Codexis Discovering Underlying Factors of Influence GlobeNewswire
Aug-20-18 07:55AM  New Research: Key Drivers of Growth for Harmonic, Astec Industries, Marlin Business Services, Arsanis, SunOpta, and Rhythm Pharmaceuticals Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Aug-14-18 08:23AM  The Daily Biotech Pulse: Cesca, Acer Therapeutics Rally On Earnings, Aridis Makes Its Nasdaq Debut Benzinga
Aug-13-18 08:00AM  Arsanis Reports Financial Results for Second Quarter 2018 GlobeNewswire -19.03%
Jul-16-18 07:26AM  Arsanis Enters Oversold Territory Zacks
Jun-28-18 01:05PM  INVESTOR ALERT: Investigation of Arsanis Announced by Holzer & Holzer Business Wire -78.01%
07:00AM  Arsanis Provides Update Following Completion of Planned Interim Analysis of Phase 2 Clinical Trial of ASN100 GlobeNewswire
Jun-14-18 08:00AM  Arsanis Out-Licenses Preclinical Stage Klebsiella pneumoniae Monoclonal Antibodies from ASN300 Program GlobeNewswire
Jun-05-18 07:50AM  Investor Expectations to Drive Momentum within Oxford Immunotec Global, Financial Engines, Brookfield Property Partners, Arsanis, QIWI, and Stitch Fix Discovering Underlying Factors of Influence GlobeNewswire
May-10-18 07:00AM  Arsanis Reports Business Highlights and Financial Results for First Quarter 2018 Business Wire
Apr-20-18 10:17AM  Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) PR Newswire
Apr-17-18 08:00AM  Arsanis to Present at the 28th European Congress of Clinical Microbiology and Infectious Diseases Business Wire +8.45%
Apr-09-18 07:40AM  Research Report Identifies Teck Resources, Adverum Biotechnologies, BeiGene, IPG Photonics, Arsanis, and G1 THERAPEUTICS with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Apr-04-18 08:00AM  Arsanis Out-Licenses Preclinical Stage E. coli Monoclonal Antibodies Business Wire +7.97%
Mar-20-18 08:00AM  Arsanis to Present at the Needham & Company 17th Annual Healthcare Conference Business Wire +9.37%
Mar-17-18 08:32AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Mar-15-18 08:10AM  Report: Exploring Fundamental Drivers Behind Mountain Province Diamonds, Limoneira, Arsanis, ExlService, Argo Group International, and Cellectis S.A. New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire +5.47%
Mar-14-18 08:00AM  Arsanis Granted Key Patents for ASN100 Covering Cross-Neutralizing S. aureus Toxin Antibodies Business Wire +5.98%
Mar-09-18 07:00AM  Arsanis Reports Financial Results and Highlights for Fourth Quarter and Full Year 2017 Business Wire
Mar-05-18 08:00AM  Arsanis to Present at the 38th Annual Cowen and Company Health Care Conference Business Wire
Dec-29-17 04:25PM  What You Must Know About Arsanis Incs (NASDAQ:ASNS) ROE Simply Wall St.
Nov-20-17 04:10PM  Arsanis Announces Closing of Initial Public Offering Business Wire
Arsanis, Inc., a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases. Its lead product candidate is ASN100, a mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia in mechanically ventilated patients. The company's preclinical pipeline comprises mAbs targeting various bacterial and viral pathogens, including respiratory syncytial virus. Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.